Prevalence of co-morbidity and its relationship to treatment among unselected patients with Hodgkin's disease and non Hodgkin's lymphoma, 1993-l996 by Spronsen, D.J. (Dick Johan) van et al.
Ann Hematol (1999) 78 :315–319 Q Springer-Verlag 1999
ORIGINAL ARTICLE
D.J. van Spronsen 7 M.L.G. Janssen-Heijnen
W.P.M. Breed 7 J.W.W. Coebergh
Prevalence of co-morbidity and its relationship to treatment among
unselected patients with Hodgkin’s disease and non-Hodgkin’s
lymphoma, 1993–1996
Received: August 31, 1998 / Accepted: February 23, 1999
M.L.G. Janssen-Heijnen (Y) 7 W.P.M. Breed
J.W.W. Coebergh
HOMAAN and HAEMOS, the Haemato-Oncology study
groups of the Comprehensive Cancer Center South (I.K.Z.),
Eindhoven, The Netherlands
J.W.W. Coebergh
Department of Epidemiology and Biostatistics,
Erasmus University Rotterdam, The Netherlands
D.J. van Spronsen, W.P.M. Breed
Department of Internal Medicine, Catharina Hospital
Eindhoven, The Netherlands
D.J. van Spronsen
Department of Internal Medicine, University Hospital
Groningen, The Netherlands
Address for Correspondence:
Dr. M.L.G. Janssen-Heijnen, Comprehensive Cancer Centre
South (I.K.Z.), P.O Box 231, 5600 AE Eindhoven,
The Netherlands,
e-mail: M.Janssen6ikz.nl,
Tel.: 0031-40-2971616, Fax: 0031-40-2971610
This study was carried out within the framework of the
Comprehensive Cancer Centre South (I.K.Z.).
Abstract A population-based series of patients with
cancer is likely to comprise more patients with serious
co-morbidity than clinical trials because of restrictive
eligibility criteria for the latter. Since co-morbidity may
influence decision-making, we studied the age-specific
prevalence of co-morbidity and its relationship to ap-
plied treatment. Data on all 194 patients with Hodg-
kin’s disease (HD) and on 904 patients with non-Hodg-
kin’s lymphoma (NHL) diagnosed between 1993 and
1996 were derived from the Eindhoven Cancer Regis-
try. In the age-group below 60 years, 87% of patients
with HD and 80% with NHL did not have a co-morbid
condition. The prevalence of serious co-morbidity was
56% for patients with Hodgkin’s disease who were
60 years and over and 43% and 61% for non Hodgkin
patients who were 60–69 years and 70 years and over,
respectively. The most common co-morbid conditions
were cardiovascular disease (18%), hypertension
(13%), chronic obstructive pulmonary disease (COPD;
13%), and diabetes mellitus (10%) for elderly Hodg-
kin’s patients. For non-Hodgkin’s patients of
60–69 years and 70 years and over, cardiovascular dis-
ease (15 and 22%, respectively), hypertension (14 and
14%, respectively), COPD (6 and 10% respectively),
and diabetes mellitus (8 and 10%, respectively) were
the most prevalent co-morbid conditions. The presence
of co-morbidity was not related to stage or grade of dis-
ease at diagnosis. In the presence of co-morbidity, 50%
less chemotherapy was administered to elderly patients
with Hodgkin’s disease and 10–15% less to elderly pa-
tients with non-Hodgkin’s lymphoma. The presence of
co-morbidity was associated with a decreased overall
survival within the first 4 months after diagnosis in both
Hodgkin’s disease and non-Hodgkin’s lymphoma for
all age-groups. In conclusion, serious co-morbidity was
found for more than half of all lymphoma patients who
were 60 years and older. Elderly patients with serious
co-morbidity received chemotherapy less often, which
is likely to affect survival adversely, as was indicated by
a decreased survival within the first 4 months after di-
agnosis.
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Introduction
Although numerous studies report successful treatment
for the great majority of patients with Hodgkin’s dis-
ease (HD), population-based survival rates are general-
ly lower, in part because they probably include more
older patients with serious co-morbidity [21, 24]. For
patients with non-Hodgkin’s lymphoma (NHL), charac-
terized by a steeply increasing incidence with age, co-
morbidity will be of even greater importance because
50% of all patients are 160 years. For elderly NHL pa-
tients staging is frequently incomplete and treatment is
not adequate [6, 12], tolerance for combination chemo-
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Table 1 Classification of co-morbidity, according to an adapted
version of Charlson et al. [5]
Chronic obstructive pulmonary disease (COPD) (medically
treated)
Cardiovascular diseases
Myocardial infarction, cardiac decompensation, angina pectoris
Intermittent claudication, abdominal aneurysm, peripheral ar-
terial disease
Cerebrovascular diseases (cerebrovascular accident, hemiplegia)
Hypertension (medically treated)
Diabetes mellitus (medically treated)
Other malignancies (except basal cell skin carcinoma and carcino-
ma in situ of the cervix)
Other
Connective tissue diseases (Besnier-Boeck disease, Wegener’s
granulomatosis, systemic lupus erythematosus)
Rheumatoid arthritis (only severe)
Kidney diseases (chronic glomerulonephritis and pyelonephri-
tis)
Bowel diseases (Crohn’s disease, ulcerative colitis)
Liver diseases (cirrhosis, hepatitis)
Dementia
Tuberculosis and other chronic infections
therapy is decreased [23], and chances for complete
remission and long-term disease-free survival are gen-
erally lower [7, 20, 22] – all presumably due to the pres-
ence of co-morbidity.
Co-morbidity may have several clinical implications.
It can influence therapeutic decision-making, it may ne-
cessitate modifications of and/or interact negatively
with a chosen therapy, and it might also be an indepen-
dent prognostic factor in itself, regardless of the thera-
py chosen [5, 6]. Co-morbidity may be a selection crite-
rion for experimental studies with restrictive eligibility
criteria, thus biasing the results with respect to the gen-
eral health-care environment. Furthermore, certain co-
morbid conditions may be associated with an increased
risk for the development of NHL, suggesting an etio-
logical relationship [4, 11].
At the request of clinicians, the Eindhoven Cancer
Registry has been collecting data on relevant co-mor-
bid diseases for all cancer patients since 1993. The vali-
dated index of co-morbidity developed by Charlson
and colleagues was used, which implies that only condi-
tions that are likely to have an independent, negative
prognostic value were included [5]. In this study the
age-specific prevalence of co-morbidity for patients
with both HD and NHL and its relationship to applied
treatment were analyzed.
Patients and methods
The Comprehensive Cancer Centre South (I.K.Z.), covering an
area with more than two million inhabitants since 1988, collects
data on patients with newly diagnosed cancer in the Dutch prov-
ince of North Brabant and the northern part of the adjacent prov-
ince of Limburg. Between 1993 and 1996, 194 patients with HD
and 904 patients with NHL were diagnosed and treated in 16 gen-
eral hospitals and two large radiotherapy institutes that collabo-
rate within the I.K.Z.
The registry officers actively collect data on diagnosis and
treatment from clinical records in the various hospitals within
6 months of diagnosis. Since 1993 co-morbidity has also been re-
corded, according to an adapted version of the list presented by
Charlson and colleagues [5]. Only prognostically relevant co-mor-
bid diseases were included (Table 1). The following sources were
used: medical history, correspondence, current medication, and
preoperative assessments. With respect to the assessment of co-
morbidity, the following rules were applied: chronic obstructive
pulmonary disease (COPD), hypertension, and diabetes mellitus
were included only if the patient was receiving current medical
treatment. Cardiovascular, cerebrovascular, and other vascular
diseases were also included after a vascular event or vascular sur-
gery. Another cancer (excluding basal cell carcinoma of the skin
and carcinoma in situ) had to have been diagnosed within the pre-
vious 10 years. During 1996 and 1997, the completeness and accu-
racy of the data on co-morbidity were checked in a series of con-
secutive patients with lung (np125), endometrial (np200), and
prostate cancer (np150) [13, 14, 18]. The attending specialist was
asked to score co-morbidity according to the same list. Recording
of co-morbidity was correct for about 80% of patients with lung
or prostate cancer and for 90% of those with endometrial cancer.
Under-registration by registry personnel was found mainly for
cardiac and other vascular diseases, because terms such as CABG
(coronary artery bypass grafting) had sometimes been disre-
garded, mainly in the beginning period.
Patients with HD were subdivided into early-stage (IA-IIA)
and advanced-stage disease (IIB-IVB), according to the Ann Ar-
bor classification [3]. Patients with NHL were subdivided into
low-grade versus intermediate/high-grade histology, according to
the Working Formulation [16].
The registry officers did not record data regarding which type
of schemes of chemotherapy were given; however, treatment
guidelines were advocated by regular multidisciplinary meetings
within the framework of the regional comprehensive cancer cen-
tre. In general, patients with early-stage HD without symptoms
received mantle-field or inverted Y-field irradiation, while more
extensive irradiation with or without chemotherapy was given in
the presence of symptoms. Patients with advanced HD generally
received chemotherapy, usually MOPP/ABVD, frequently fol-
lowed by iceberg irradiation. Patients with early-stage low-grade
NHL usually received involved-field irradiation, while for pa-
tients with advanced stages generally a wait-and-see policy was
followed or chemotherapy (usually COP) was given, with or with-
out involved-field irradiation. Patients with intermediate and high
grade NHL generally received CHOP or CNOP chemotherapy,
with or without involved field irradiation. Patients with lympho-
blastic NHL received the same chemotherapeutic treatment as in
acute lymphoblastic leukemia.
We analyzed the age-specific prevalence of co-morbidity for
both HD and NHL patients. For HD we analyzed the association
between co-morbidity and choice of treatment according to stage
of the disease, for NHL according to grade. Grade remained un-
classified for 254 NHL patients who had extranodal and skin lym-
phomas. Differences between groups were determined using the
chi-square test. Since follow-up results were available for only the
first 4 months, survival within 4 months was calculated according
to age-group.
Results
NHL was diagnosed five times more often than HD.
The mean age of HD patients was 40 years (range
5–81), NHL patients 61 years (range 16–93). NHL and
HD were more frequently diagnosed among males, at
57% and 62%, respectively. Co-morbidity was more
prevalent among male 660 years (63% and 55%) than
317
Table 2 Age-specific prevalence of co-morbiditya among 194 HD patients and 904 NHL patients diagnosed in 1993–1996 in the south-
eastern Netherlands
Hodgkin’s disease Non-Hodgkin’s lymphoma
~60 years (%) 660 years (%) ~60 years (%) 60–69 years (%) 670 years (%)
No co-morbidity 87 44 80 57 39
COPD 6 13 2 6 10
Cardiovascular 1 18 3 15 22
Cerebrovascular 1 – 1 3 6
Hypertension 3 13 6 14 14
Diabetes mellitus 2 10 1 8 10
Other malignancy 1 3 4 9 14
Other 3 15 5 9 12
(np) (155) (39) (372) (222) (310)
a Total is 1100% because some patients suffered from two or more co-morbid conditions.
female (47% and 52%) patients with HD and NHL, re-
spectively. Subdivision of NHL according to grade was
as follows: low-grade 22%, intermediate-grade 43%,
high-grade 7%, and unknown 28%. Subdivision of HD
according to stage was as follows: early-stage 56%, ad-
vanced-stage 37%, and unknown 7%. Cardiovascular
disease was the most common co-morbid condition in
both HD and NHL, with a prevalence of almost 20% in
patients aged 60 years and older (Table 2).
For newly diagnosed HD patients the prevalence of
serious co-morbidity was 22%; it was 13% for patients
below 60 years and 56% for patients 60 years and older
(p~0.0001). The prevalence of co-morbidity among pa-
tients with early-stage (Ia–IIa) was similar to that for
advanced-stage (IIB–IVB) disease (data not shown).
Of the newly diagnosed NHL patients, 40% had at
least one co-morbid condition: 20% of all patients
younger than 60 years, 43% for patients of 60–69 years,
and a steeply increasing prevalence of 61% in patients
over 70 years (p~0.0001). The prevalence of co-mor-
bidity among patients with low-grade NHL was similar
to that for intermediate/high-grade NHL (data not
shown).
Chemotherapy was administered to 75% of patients
with HD without co-morbidity versus 50% with co-
morbidity (p~0.01). Among elderly Hodgkin’s patients
with co-morbidity the proportion receiving chemother-
apy was 50% lower than that for elderly patients with-
out co-morbidity (p~0.01); these differences were less
pronounced for patients younger than 60 years
(pp0.15) (Table 3). In particular, elderly patients with
early-stage HD and a co-morbid condition received
chemotherapy much less often (90% versus
33%,pp0.05).
Chemotherapy was administered less often to elder-
ly patients with low-grade and intermediate/high-grade
NHL (p~0.001) than to younger patients, regardless of
the presence of co-morbidity (Table 4). In addition to
being dependent on age, the administration of chemo-
therapy to patients 60 years and older with interme-
diate/high-grade NHL further decreased in the event of
co-morbidity (pp0.04).
Table 3 Administration of primary chemotherapy to 194 patients
with Hodgkin’s disease, according to age and presence of co-mor-
bidity
Administration of primary chemotherapy
~60 years 660 years
Co-morbidity
No 73% 94% pp0.1
Yes 50% 50% pp0.8
pp0.15 p~0.01
Survival within the first 4 months after diagnosis was
decreased in the presence of co-morbidity in both NHL
and HD for all age-groups (Table 5).
Discussion
The most common co-morbid diseases were cardiovas-
cular diseases, COPD, and hypertension for HD pa-
tients and cardiovascular diseases, hypertension, other
malignancies, and diabetes mellitus for NHL patients.
More than half of all patients 60 years and older suf-
fered from at least one co-morbid condition. Co-mor-
bidity appeared to be more prevalent among NHL pa-
tients, presumably due to the higher mean age.
Our age-specific prevalence rates for chronic dis-
eases did not differ markedly from 4-year prevalence
data found for Dutch general practices; both increased
with age [17], as was also seen in an analysis of co-mor-
bidity among patients with breast cancer [19].
The presence of co-morbidity appeared to discou-
rage the choice of systemic chemotherapy, especially
for elderly patients; this will probably have an adverse
impact on long-term survival, as was indicated by a de-
creased survival within 4 months after diagnosis. For
elderly Hodgkin’s patients, combination chemotherapy
has been found to produce good results in our region
[8, 21]. Since combination chemotherapy offers the best
chance for cure, it is the treatment of first choice for
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Table 4 Administration of pri-
mary chemotherapy to pa-
tients with NHL according to
grade, age, and presence of
co-morbidity
Administration of primary chemotherapy
NHL grade ~60 years 60–69 years 670 years
Low (n) 96 53 50
Co-morbidity
No 64% 45% 33% pp0.02
Yes 50% 38% 25% ppns
ppns ppns ppns
Intermediate/high (n) 192 104 155
Co-morbidity
No 85% 87% 58% p~0.001
Yes 85% 79% 52% p~0.0005
ppns ppnsa ppnsa
a pp0.04 when patients 60–69 years and 670 years are grouped together.
Table 5 Overall survival (%)
within the first 4 months after
diagnosis in patients with
NHL and HD, according to
age
NHL HD
Co-morbidity ~60 years (%) 60–69 years (%) 670 years (%) ~60 years (%) 660 years (%)
No 93 89 80 100 88
Yes 85 84 70 95 73
patients with intermediate/high-grade NHL [9]. How-
ever, elderly NHL patients reportedly receive chemo-
therapy less often [6]. This finding was confirmed by
our study and was even independent of the presence of
co-morbidity. Moreover, we found that the administra-
tion of chemotherapy is also reduced in the presence of
co-morbidity, especially for elderly patients with inter-
mediate/high-grade NHL. Obviously, the reduced ad-
ministration of systemic chemotherapy is likely to in-
fluence survival adversely, especially since intermediate
and high-grade lymphomas in the elderly are reported
to be aggressive diseases with adverse prognostic pa-
rameters [2].
Our findings are in agreement with studies which
have demonstrated that cancer patients with extensive
co-morbidity are treated less aggressively than those
with milder co-morbid conditions, independent of the
effects of age and stage of disease [10, 19]. Moreover, a
greater influence of co-morbidity than age, not only on
therapeutic decision-making in lung and colorectal can-
cer [11, 15] but also on long-term survival of men with
localized prostate cancer, has been reported [1]. This
negative influence of co-morbidity on the survival of
cancer patients might be due to several mechanisms:
the increased risk of death due to the co-morbid condi-
tion itself, more contraindications for anticancer treat-
ment, more indications for dose reduction, and a higher
rate of treatment-related complications such as infec-
tions and cardiovascular events.
Whether the shift towards less frequent administra-
tion of chemotherapy for lymphoma patients with co-
morbidity is justified or not needs to be further investi-
gated by assessing its influence on long-term survival.
Moreover, the influence of co-morbidity on staging and
adherence to treatment guidelines requires elucida-
tion.
In conclusion, co-morbidity was present in more
than half of all lymphoma patients who were 60 years
and older. In the presence of co-morbidity elderly lym-
phoma patients received chemotherapy much less oft-
en, which is likely to affect survival adversely, as was
indicated by a decreased survival within 4 months after
diagnosis.
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